Literature DB >> 29930864

Macrophages in Nonalcoholic Steatohepatitis: Friend or Foe?

Joel Grunhut1, Wei Wang1, Berk Aykut1, Inderdeep Gakhal1, Alejandro Torres-Hernandez1, George Miller1,2.   

Abstract

Nonalcoholic steatohepatitis (NASH) is a subtype of nonalcoholic fatty liver disease that is characterised by steatosis, chronic inflammation, and hepatocellular injury with or without fibrosis. The role and activation of macrophages in the pathogenesis of NASH is complex and is being studied for possible therapeutic options to help the millions of people diagnosed with the disease. The purpose of this review is to discuss the pathogenesis of NASH through the activation and role of Kupffer cells and other macrophages in causing inflammation and progression of NASH. Furthermore, this review aims to outline some of the current therapeutic options targeting the pathogenesis of NASH.

Entities:  

Keywords:  Inflammation; macrophage; steatohepatitis

Year:  2018        PMID： 29930864      PMCID： PMC6007994     

Source DB:  PubMed          Journal:  Eur Med J Hepatol        ISSN： 2053-4221


  69 in total

1.  CHOP and AP-1 cooperatively mediate PUMA expression during lipoapoptosis.

Authors:  Sophie C Cazanave; Nafisa A Elmi; Yuko Akazawa; Steven F Bronk; Justin L Mott; Gregory J Gores
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2010-04-29       Impact factor: 4.052

2.  Kupffer cells and activation of endothelial TLR4 coordinate neutrophil adhesion within liver sinusoids during endotoxemia.

Authors:  Braedon McDonald; Craig N Jenne; Lisheng Zhuo; Koji Kimata; Paul Kubes
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-10-10       Impact factor: 4.052

Review 3.  Effects of fatty acid bile acid conjugates (FABACs) on biliary lithogenesis: potential consequences for non-surgical treatment of gallstones.

Authors:  Fred M Konikoff; Tuvia Gilat
Journal:  Curr Drug Targets Immune Endocr Metabol Disord       Date:  2005-06

4.  M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease.

Authors:  Jinghong Wan; Merieme Benkdane; Fatima Teixeira-Clerc; Stéphanie Bonnafous; Alexandre Louvet; Fouad Lafdil; Françoise Pecker; Albert Tran; Philippe Gual; Ariane Mallat; Sophie Lotersztajn; Catherine Pavoine
Journal:  Hepatology       Date:  2013-11-20       Impact factor: 17.425

Review 5.  PPARβ in macrophages and atherosclerosis.

Authors:  G Chinetti-Gbaguidi; B Staels
Journal:  Biochimie       Date:  2016-12-21       Impact factor: 4.079

Review 6.  Inflammasomes in liver diseases.

Authors:  Gyongyi Szabo; Timea Csak
Journal:  J Hepatol       Date:  2012-05-23       Impact factor: 25.083

7.  Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance.

Authors:  Durba Pal; Suman Dasgupta; Rakesh Kundu; Sudipta Maitra; Gobardhan Das; Satinath Mukhopadhyay; Sukanta Ray; Subeer S Majumdar; Samir Bhattacharya
Journal:  Nat Med       Date:  2012-07-29       Impact factor: 53.440

8.  Transgenic expression of human neutrophil peptide-1 enhances hepatic fibrosis in mice fed a choline-deficient, L-amino acid-defined diet.

Authors:  Rie Ibusuki; Hirofumi Uto; Shiho Arima; Seiichi Mawatari; Yoshiko Setoguchi; Yuji Iwashita; Shinichi Hashimoto; Takuro Maeda; Shiro Tanoue; Shuji Kanmura; Makoto Oketani; Akio Ido; Hirohito Tsubouchi
Journal:  Liver Int       Date:  2013-05-20       Impact factor: 5.828

9.  Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis.

Authors:  Michael Kremer; Emmanuel Thomas; Richard J Milton; Ashley W Perry; Nico van Rooijen; Michael D Wheeler; Steven Zacks; Michael Fried; Richard A Rippe; Ian N Hines
Journal:  Hepatology       Date:  2010-01       Impact factor: 17.425

10.  Death Receptor-Mediated Cell Death and Proinflammatory Signaling in Nonalcoholic Steatohepatitis.

Authors:  Petra Hirsova; Gregory J Gores
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2015-01
View more
  21 in total

Review 1.  Mitochondrial dysfunction in nonalcoholic fatty liver disease and alcohol related liver disease.

Authors:  Pankaj Prasun; Ilona Ginevic; Kimihiko Oishi
Journal:  Transl Gastroenterol Hepatol       Date:  2021-01-05

2.  Exogenous PP2A inhibitor exacerbates the progression of nonalcoholic fatty liver disease via NOX2-dependent activation of miR21.

Authors:  Muayad Albadrani; Ratanesh K Seth; Sutapa Sarkar; Diana Kimono; Ayan Mondal; Dipro Bose; Dwayne E Porter; Geoff I Scott; Bryan Brooks; Samir Raychoudhury; Mitzi Nagarkatti; Prakash Nagarkatti; Yvon Jule; Anna Mae Diehl; Saurabh Chatterjee
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-08-08       Impact factor: 4.052

Review 3.  The Role of Innate Immune Cells in Nonalcoholic Fatty Liver Disease.

Authors:  Marina Nati; Kyoung-Jin Chung; Triantafyllos Chavakis
Journal:  J Innate Immun       Date:  2021-08-24       Impact factor: 7.349

4.  Oxy210, a Semi-Synthetic Oxysterol, Exerts Anti-Inflammatory Effects in Macrophages via Inhibition of Toll-like Receptor (TLR) 4 and TLR2 Signaling and Modulation of Macrophage Polarization.

Authors:  Feng Wang; Frank Stappenbeck; Liu-Ya Tang; Ying E Zhang; Simon T Hui; Aldons J Lusis; Farhad Parhami
Journal:  Int J Mol Sci       Date:  2022-05-13       Impact factor: 6.208

Review 5.  Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors.

Authors:  Sven Francque; Gyongyi Szabo; Manal F Abdelmalek; Christopher D Byrne; Kenneth Cusi; Jean-François Dufour; Michael Roden; Frank Sacks; Frank Tacke
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-10-22       Impact factor: 46.802

6.  Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH.

Authors:  Rebeca Escutia-Gutiérrez; J Samael Rodríguez-Sanabria; C Alejandra Monraz-Méndez; Jesús García-Bañuelos; Arturo Santos-García; Ana Sandoval-Rodríguez; Juan Armendáriz-Borunda
Journal:  Sci Rep       Date:  2021-06-03       Impact factor: 4.379

7.  PKM2-dependent metabolic skewing of hepatic Th17 cells regulates pathogenesis of non-alcoholic fatty liver disease.

Authors:  Maria E Moreno-Fernandez; Daniel A Giles; Jarren R Oates; Calvin C Chan; Michelle S M A Damen; Jessica R Doll; Traci E Stankiewicz; Xiaoting Chen; Kashish Chetal; Rebekah Karns; Matthew T Weirauch; Lindsey Romick-Rosendale; Stavra A Xanthakos; Rachel Sheridan; Sara Szabo; Amy S Shah; Michael A Helmrath; Thomas H Inge; Hitesh Deshmukh; Nathan Salomonis; Senad Divanovic
Journal:  Cell Metab       Date:  2021-05-17       Impact factor: 31.373

Review 8.  Human biomimetic liver microphysiology systems in drug development and precision medicine.

Authors:  Albert Gough; Alejandro Soto-Gutierrez; Lawrence Vernetti; Mo R Ebrahimkhani; Andrew M Stern; D Lansing Taylor
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-12-17       Impact factor: 73.082

Review 9.  Targeting Myeloid-Derived Cells: New Frontiers in the Treatment of Non-alcoholic and Alcoholic Liver Disease.

Authors:  Luisa Vonghia; Mikhaïl A Van Herck; Jonas Weyler; Sven Francque
Journal:  Front Immunol       Date:  2019-03-27       Impact factor: 7.561

Review 10.  Intercellular Communication between Hepatic Cells in Liver Diseases.

Authors:  Keisaku Sato; Lindsey Kennedy; Suthat Liangpunsakul; Praveen Kusumanchi; Zhihong Yang; Fanyin Meng; Shannon Glaser; Heather Francis; Gianfranco Alpini
Journal:  Int J Mol Sci       Date:  2019-05-02       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.